Dehaier Medical Announces Improved Sleep Diagnostics Device
November 07 2013 - 8:30AM
Dehaier Medical Systems Ltd. (Nasdaq:DHRM)
("Dehaier" or the "Company"), an emerging leader in development,
assembly, marketing and sales of medical devices and homecare
medical products, announced today that it has completed research
and development for its new DHR-998 sleep diagnostics device. The
new device is a technological upgrade based on the original high
efficiency sleep diagnostic and monitoring product. The device,
which features an enhanced and more user-friendly operating system,
analyzes user respiratory quality more accurately across five
testing variables, PPG (plethysmograph), oxygen saturation, heart
rate, snoring and body position.
Mrs. Rayna Dong, Dehaier's Marketing Director, commented, "We
have listened to feedback from doctors, patients, distributors and
manufacturers to improve our already-powerful sleep diagnostics
product. We added two new important channels to improve the
accuracy of sleep diagnosis. We also enhanced the user interface to
make the device's features even easier to use and optimized the
operating system. We expect the new device will be ready to enter
market near the end of this year. We plan to attend domestic and
international exhibitions to show the world the new device
beginning in 2014."
About Dehaier Medical Systems Ltd.
Dehaier is an emerging leader in the development, assembly,
marketing and sale of medical products, including respiratory and
oxygen homecare medical products. The company develops and
assembles its own branded medical devices and homecare medical
products from third-party components. The company also distributes
products designed and manufactured by other companies, including
medical devices from IMD (Italy), Welch Allyn (USA), HEYER
(Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). More
information may be found at http://www.dehaier.com.cn
Forward-looking Statements
This news release contains forward-looking statements as defined
by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events, government approvals
or performance, and underlying assumptions and other statements
that are other than statements of historical facts, including in
particular any implications regarding the sleep diagnostic device.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, future developments
in payment for and demand for medical equipment and services, and
other risks contained in reports filed by the company with the
Securities and Exchange Commission. All such forward-looking
statements, whether written or oral, and whether made by or on
behalf of the company, are expressly qualified by the cautionary
statements and any other cautionary statements which may accompany
the forward-looking statements. In addition, the company disclaims
any obligation to update any forward-looking statements to reflect
events or circumstances after the date hereof.
CONTACT: Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn
Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn
Lianluo Smart (NASDAQ:LLIT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lianluo Smart (NASDAQ:LLIT)
Historical Stock Chart
From Jul 2023 to Jul 2024